Trials / Completed
CompletedNCT05098678
Zinc Supplementation and Behçet's Syndrome
The Effects of Zinc Gluconate Supplementation on Several Genes Expression, the Serum Level of Inflammatory Factors, Quality of Life, and Disease Activity in Patients With Behcet Syndrome: Double-blind Randomized Controlled Clinical Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Tabriz University of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 20 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
To study the effects of zinc gluconate supplementation on patients with Behçet's syndrome, 50 patients will be randomly allocated to two groups: placebo group or zinc group (one tablet of 30 mg/day elemental zinc) for 12 weeks. All participants will be asked not to alter their diet, medication, and physical activity during the study. At the first and the end of the intervention, genes and proteins expression, the serum level of inflammatory factors, quality of life, disease activity, anthropometric measures, physical activity and serum level of zinc will be assessed and compared between groups.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Zinc gluconate | 120 mg each tablet containing 30 mg elemental zinc |
| DIETARY_SUPPLEMENT | Placebo | Placebo (microcrystalline cellulose): 1 tablet (120 mg each) |
Timeline
- Start date
- 2020-08-22
- Primary completion
- 2021-05-22
- Completion
- 2021-09-22
- First posted
- 2021-10-28
- Last updated
- 2021-11-04
Locations
1 site across 1 country: Iran
Source: ClinicalTrials.gov record NCT05098678. Inclusion in this directory is not an endorsement.